Clinical trial TACTIVE-U
An interventional safety and efficacy phase 1B/2, open-label umbrella study to investigate tolerability, PK, and antitumor activity of vepdegestrant (AVR-471/PF-07850327), an oral proteolysis targeting chimera, in combination with other anticancer treatments in participants aged 18 and older with ER+ advanced or metastatic breast cancer, sub-study C (AVR-471 in combination with samuraciclib
| Organ | Breast |
|---|---|
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Pfizer |
| EudraCT Identifier | 2023-507125-41-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05548127 |
| Last update |